Compare Phillips 66 (PSX) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Phillips 66 vs Revvity Inc — how do they compare? Phillips 66 trades at $278 (market cap $112.36B), while Revvity Inc trades at $154.1 (market cap $16.98B). The key difference: Phillips 66 is far larger — about 6.6× Revvity Inc's market cap, and Phillips 66 pays the higher dividend (1.8%). Which is the better fit depends on your goals — on Pluang, investors hold Phillips 66 for 62 Days and Revvity Inc for 12 Days on average.
| PSX | RVTY | |
|---|---|---|
Market Cap | $112.36B | $16.98B |
Volume | 2,374,751 | 1,456,900 |
Sector | Energy | Health |
52-Week High | $281.60 | $157.36 |
52-Week Low | $126.76 | $82.26 |
Typical Hold Time | 62 Days | 12 Days |
Enterprise Value | $128.83B | $19.30B |
Dividend Yield | 1.8% | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Phillips 66 (PSX) trades at $278.18, up 2.42% with strong technical momentum as it approaches resistance near $280. The stock shows robust fundamentals with a P/E of 16.07 and ROE of 24.02%, supported by three consecutive earnings beats. Recent news highlights structural refining advantages and AI-driven operational improvements, while analyst consensus remains bullish with a $279 price target.
PSX offers attractive valuation metrics and strong profitability, though revenue declines from 2022-2025 present headwinds. Key risks include refining margin volatility and potential diesel export restrictions. With institutional support and positive earnings trajectory, the stock presents a compelling opportunity for value-oriented investors despite cyclical industry exposure.
RVTY trades at $155.01, up 0.92% with a bullish technical outlook. The stock shows strong earnings momentum with three consecutive quarterly beats and maintains solid profitability with 54.98% gross margins. Recent developments include new product launches in Europe and strategic acquisitions to expand metabolic disease research capabilities.
The investment case balances premium valuation (P/E 73.15) against consistent execution and growth initiatives. Key risks include China market pressures and margin compression, while analyst consensus remains positive with 52% buy ratings. Upside potential exists if Q3 earnings meet expectations in November.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
